Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

References

• Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 185–187.
   Google Scholar
• Matutes E, Oscier D, Montalban C, et al. Splenic marginal-zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487–495.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol. 1999;36:148–154.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95–103.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004;101: 2050–2057.
   PubMed Web of Science ®Google Scholar
• Franco V, Florena AM, Campesi G. Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma. Histopathology 1996;29:571–575.
   PubMed Web of Science ®Google Scholar
• Audouin J, Le Tourneau A, Molina T, et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003;122:404–412.
   PubMed Web of Science ®Google Scholar
• Zhu D, Orchard J, Oscier DG, et al. V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood 2002;100:2659–2961.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimitriadou E, et al. Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Res 2009;5: 1811–1816.
   Google Scholar
• Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma:proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005;106:1831–1838.
   PubMed Web of Science ®Google Scholar
• Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 2012;26:1638–1646.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100:107–115.
   PubMed Web of Science ®Google Scholar
• Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010;116:1479–1488.
   PubMed Web of Science ®Google Scholar
• Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012;209:1537–1551.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Bryan L, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209:1553–1565.
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Baseggio L, Salles G, et al. Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity. Discov Med 2012;13:253–265.
   PubMedGoogle Scholar
• Ponzoni M, Kanellis G, Pouliou E, et al. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?Am J Surg Pathol 2012;36: 1609–1618.
   PubMed Web of Science ®Google Scholar
• Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648–1654.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41–47.
   PubMedGoogle Scholar
• Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731–736.
   PubMed Web of Science ®Google Scholar
• Parry-Jones N, Matutes E, Gruszca-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120:759–764.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107:4643–4649.
   PubMed Web of Science ®Google Scholar
• Montalban C, Arbraira V, Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate deydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2012;159:164–171.
   PubMed Web of Science ®Google Scholar
• Montalban C, Abraira V, Arcaini L, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 2013 Jul 29. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mulligan SP, Matutes E, Dearden C, et al. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206–209.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006;107:125–135.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab: progress report and comparison with splenectomy. Oncologist 2013;18:190–197.
   PubMed Web of Science ®Google Scholar
• Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012;159:322–328.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000;14:573–575.
   PubMed Web of Science ®Google Scholar
• Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997;99:158–161.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005;75:130–135.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000;40:113–117.
   PubMed Web of Science ®Google Scholar
• Riccioni R, Caracciolo F, Galimberti S, et al. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003;21:163–168.
   PubMed Web of Science ®Google Scholar
• Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005;90:856–858.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007;25:127–131.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Rituximab monotherapy is the treatment of choice for splenic marginal zone lymphoma (SMZL). Ann Oncol 2008;19(Suppl.): Abstract 367.
   Google Scholar
• Fabbri A, Gozzetti A, Lazzi S, et al. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006;6:496–499.
   PubMedGoogle Scholar
• Paydas S, Yavuz S, Disel U, et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma 2003;44:2165–2166.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4:250–252.
   PubMedGoogle Scholar
• Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009;145:741–748.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010;21:851–854.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Pelosini M, et al. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Ann Oncol 2013;24:2434–2438.
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89–94.
   PubMed Web of Science ®Google Scholar
• El Weshi A, Ribrag V, Girinski T, et al. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol 1998;103: 1212–1213.
   PubMed Web of Science ®Google Scholar
• Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001;91: 294–301.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Dutia M, Deroock I, Reed-Pease C, et al. Lenalidomide overcomes FcγRIIIa-mediated resistance to rituximab in patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL): a correlative analysis of a phase 2 study. Blood 2010;116(Suppl. 1): Abstract 3967.
   Google Scholar
• Samaniego F, Hagemeister F, McLaughlin P, et al. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011;29(Suppl.): Abstract 8030.
   Google Scholar
• Kahl B, Byrd J, Flinn I, et al. Clinical safety and activity in a phase 1 study of Cal-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.
   Google Scholar
• Spurgeon S, Okada C, Huang J, et al. Targeting the epigenome: a phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies. J Clin Oncol 2010;28(15 Suppl.): Abstract TPS 301.
   Web of Science ®Google Scholar
• Neiman RS, Sullivan AL, Jaffe R. Malignant lymphoma simulating leukemic reticuloendotheliosis: a clinicopathologic study of ten cases. Cancer 1979;43:329–342.
   PubMed Web of Science ®Google Scholar
• Palutke M, Tabaczka P, Mirchandani I, et al. Lymphocytic lymphoma simulating hairy cell leukemia: a consideration of reliable and unreliable diagnostic features. Cancer 1981;48:2047–2055.
   PubMed Web of Science ®Google Scholar
• Melo JV, Robinson DS, Gregory C, et al. Splenic B cell lymphoma with “villous” lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia 1987;1:294–298.
   PubMed Web of Science ®Google Scholar
• Melo JV, Hegde U, Parreira A, et al. Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol 1987;40:642–651.
   PubMed Web of Science ®Google Scholar
• Isaacson PG, Matutes E, Burke M, et al. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994 1;84: 3828–3834.
   Web of Science ®Google Scholar
• Boussiotis VA, Kittas C, Pangalis GA. Splenic lymphoma with villous lymphocytes: a distinct entity to be differentiated from hairy cell leukemia. Iatriki 1991;60:469–476.
   Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase III, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520–531.
   PubMed Web of Science ®Google Scholar